Introduction: An estimated 1,399 new cases of pancreatic cancer (PC) and 1,406 deaths from the same cause occurred in Colombia in 2002. We evaluate the costeffectiveness of multidetector computed tomography (CT), endoscopic ultrasonography (EUS) and positron emission tomography with computed tomography (PET/CT) in diagnosis and staging of patients with clinical suspicion of PC.
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Introduction
Pancreatic cancer (PC) is responsible for approximately 40,000 deaths annually in the United States and Europe (1-2). 1,399 new cases and 1,406 deaths from this disease were estimated for Colombia in 2002 (1) . Surgery is currently the only curative option for these patients; however, many of them develop early recurrence of the disease within the first 6-12 months after surgery. The poor prognosis is related to the aggressive characteristics of the disease and the presence of extra-pancreatic tumours not found during the assessment prior to surgery.
Multidetector CT, endoscopic ultrasonography (EUS) and more recently positron emission tomography over computed tomography (PET/CT) are used as diagnostic tools in the staging of the disease, whose objective is to determine tumor resectability and the metastasis detection. Assessment of tumor resectability has important implications for surgical management, because a resectable tumor undergoes surgery with curative intent, which has a high morbidity with no benefits in patients with unresectable or metastatic PC (3) (4) (5) .
This study aims to assess the cost-effectiveness of using CT, EUS and PET/CT in the diagnosis and management of patients with clinical suspicion of PC on the setting of the Colombian population.
Methodology
To evaluate the cost-effectiveness of diagnostic strategies in patients with suspected PC, we built a decision tree to evaluate the following strategies: 1) EUS, 2) multidetector CT and 3) PET/CT, 4) CT plus EUS used in series or in parallel ( Figure 1) . The model took into account the sensitivity and specificity indicators for cancer detection and resectability assessment for each of the diagnostic tests included. As a measure of effectiveness we used the number of appropriate treatment behaviours, considering a proper conduct when the diagnostic test detects the PC and adequately assesses it as resectable or unresectable. The time horizon was less than one year (time from initial evaluation until histological confirmation of resectability after surgery). No discount rate was applied because the time horizon was short.
Clinical data
We conducted a systematic literature review, which extracted sensitivity and specificity data for detection of PC and resectability for each of the diagnostic tests. The PC prevalence data in patients with clinical suspicion of this disease, and the proportion of tumors that are resectable were obtained from locally conducted studies (6-12). Table 1 shows the parameters used in the model with the respective ranges used in sensitivity analysis.
Cost data
The perspective was that of the third payer, and we only included direct costs related to the administration of the tests, diagnostic procedures, surgical treatment and management of complications (Table 2 ). Costs were calculated according to the tariff rates of the official insurance handbook (SOAT).
Economic Analysis
We estimated the incremental cost-effectiveness ratios (ICER), built the efficiency curve, performed univariate and probabilistic sensitivity analysis for cost and clinical data, and calculated the acceptability curves and confidence regions on the effectiveness plane.
Results
The PET/CT strategy was more costly and less effective, taking appropriate behavior in only 69.2% of cases. The strategy based on CT plus EUS used in series to assess resectability was the most effective in taking the appropriate behavior for 79.7% of cases (Table 3) .
The strategy based on CT alone had the best cost-effectiveness ICER (Col$ 3,397,163 for each appropriate behaviour), the cost of changing this strategy to CT plus EUS used in series was Col$ 7,893,573 for each additional appropriate behaviour gained. Figure 2 shows the efficiency frontier. The strategies with multidetector CT and CT plus EUS used in series fall on the curve, while that the strategies PET/CT, CT plus EUS used in parallel and EUS alone are dominated.
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Sensitivity analysis Univariate analysis of costs showed that costs per hospitalization day, the cost of pancreaticoduodenectomy and cost of CT are the variables that affect the cost-effectiveness ratios. For costs per hospitalization day lower than Col$ 175,000, EUS becomes a cost-effective strategy; and for cost for CT higher than Col$ 1,270,000, the cost-effective strategy is EUS.
The clinical variables affecting the cost-effectiveness ratios are: the specificities of CT and EUS to assess resectability, the prevalence of PC in patients with clinical suspicion, the sensitivity of CT for the detection of PC, and the proportion of PC cases resectable at diagnosis. For a specificity of the assessment of resectability of CT below 53% and above 70% for EUS, prevalence of cancer less than 76% and PC ratios resectable at diagnosis greater than 50%, the strategy is EUS becomes efficient and TAC plus EUS strategy ceases to be efficient and becomes a dominated strategy.
Probabilistic sensitivity analysis
We performed 10,000 Monte Carlo simulations. Figure 3 shows the confidence region on the plane of incremental effectiveness for CT plus EUS in series compared with multidetector CT. For WTP per additional unit of effectiveness of Col$ 7,600,000, the strategy of CT plus EUS serial is costeffective in 50% of the simulations (area below the diagonal), indicating that for this threshold there is uncertainty about whether this strategy is costeffective. Figure 4 shows the acceptability curves for different management strategies in patients with clinical suspicion of PC. For a WTP per additional effectiveness unit greater than or equal to Col$ 9,000,000 the cost-effective strategy is EUS, whereas for smaller values CT becomes cost-effective.
Conclusions
Assessment of resectability of pancreatic tumours at diagnosis is important in determining the surgical procedure with curative intent and due to the significant occurrence of this type of tumour in the Colombian population is important for the economic analysis of different diagnostic alternatives to be funded by the health system. Several studies have demonstrated the cost-effectiveness of imaging in determining resectability of pancreatic tumours on imaging methods (6, 13-14), but had not compared the three PC diagnostic imaging procedures.
From the economic point of view the cost-effective strategy for assessing patients with clinical suspicion of PC is multidetector CT at a price for examination up to Col$ 583,773. Diagnosis/ staging of PC based CT plus EUS used in series or EUS alone to assess resectability become cost-effective for WTP higher than or equal to Col$ 7,893 573, and Col$ 9,000,000, respectively.
The limitations of this study are related to the dependency of the estimates of cost-effectiveness on indicators that were estimated from the literature because, although their precise values are different for each strategy, the ranges overlap in some cases. In the case of the parameters of sensitivity and specificity of CT and PET/CT, this may result in no differences in diagnosis, as the probabilistic analysis could not find significant differences. Furthermore, the studies included in this study estimated the parameters for patients with symptoms of pancreatic cancer, but in Colombia the diagnosis is usually made in advanced stages of disease where the prognosis is more discouraging (12). 
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